Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP104 dose-escalation study in primary biliary cholangitis
NL-OMON41920Phase 2Active, not recruiting
- Sponsor
- Fast Forward Pharmaceuticals BV
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FFP104 in primary biliary cholangitis (PBC) (4 arms), sponsored by Fast Forward Pharmaceuticals BV. Primary endpoints: Safety and tolerability of repeat-dose FFP104 and Pharmacokinetics and exploratory efficacy. Started May 2015; status: active, not recruiting.
02
Drugs
FFP104
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON41920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41920.